From Process Development to Commercial Supply: Scalable Platforms for Efficient ADC Development and Manufacturing - 17th World ADC San Diego

Your Flagship Event Driving ADC Innovation, Insights & Connections

Pfizer pens $10B, 12-drug deal with Innovent in broad bet on Chinese cancer med innovation
Iza-Bren Is Approved in China for Recurrent/Metastatic Nasopharyngeal Carcinoma
Novartis to acquire Myricx Bio for up to $1.5B, adding cancer-fighting ADC payload platform
Daiichi, AstraZeneca’s Enhertu breaks into early breast cancer with dual FDA approvals
Gilead’s Trodelvy nabs broad FDA approval in front-line TNBC, fueling TROP2 ADC market war
J&J makes $1B upfront bet on emerging DAC space by netting Firefly Bio

From Process Development to Commercial Supply: Scalable Platforms for Efficient ADC Development and Manufacturing

12:30 pm - Tuesday 13th October 2026

Breaking down flexible platform strategies to translate conjugation chemistry into commercially viable process
Laying out case study-based CMC insights highlighting critical technical levers for successful ADC scale-up and technology transfer
Understanding how an integrated CDMO framework can de-risk ADC scale-up by aligning early process-development decisions with cost of goods, supply-chain resilience, and regulatory CMC expectations from IND through BLA

Speakers:

Tiejun Li

Tiejun Li

Vice General Manager & Head, CMC & PM

AsymBio